The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: A pilot in vivo study

Journal of Digestive Diseases

Volumn 12, Issue 5, 2011, Pages 349-356

  Tan, Hong Hong ^a   Ge, Zhi Zheng ^a   Gao, Yun Jie ^a   Chen, Hui Min ^a   Fang, Jing Yuan ^a   Chen, Hai Ying ^a   Liu, Wen Zhong ^a   Xiao, Shu Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiopoietin 2; Delta like ligand 4; Gastrointestinal; Hypoxia inducible factor 1; Notch1; Vascular malformation

Indexed keywords

ANGIOPOIETIN 2; DELTA LIKE LIGAND 4; HYPOXIA INDUCIBLE FACTOR 1; NOTCH1 RECEPTOR; PROTEIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONGENITAL BLOOD VESSEL MALFORMATION; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MALFORMATION; GASTROINTESTINAL VASCULAR MALFORMATION; HUMAN; IN VIVO STUDY; IRON THERAPY; LETHARGY; MALE; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE;

ANGIOPOIETIN-2; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PILOT PROJECTS; RECEPTOR, NOTCH1; RECURRENCE; THALIDOMIDE; VASCULAR MALFORMATIONS;

EID: 80053407782     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00506.x     Document Type: Article

References (35)

1. Regula J, Wronska E, Pachlewski J. Vascular lesions of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2008; 22: 313-28.
2. Hodgson H. Hormonal therapy for gastrointestinal angiodysplasia. Lancet 2002; 359: 1630-1.
3. Ell C, Remke S, May A, Helou L, Henrich R, Mayer G. The first prospective controlled trial comparing wireless capsule endoscopy with push enteroscopy in chronic gastrointestinal bleeding. Endoscopy 2002; 34: 685-9.
4. Macdonald J, Porter V, Scott NW, McNamara D. Small bowel lymphangiectasia and angiodysplasia: a positive association; novel clinical marker or shared pathophysiology? J Clin Gastroenterol 2010; 44: 610-4.
5. Plummer JM, Gibson TN, Mitchell DI, Herbert J, Henry T. Emergency subtotal colectomy for lower gastrointestinal haemorrhage: over-utilised or under-estimated? Int J Clin Pract 2009; 63: 865-8.
6. Dodda G, Trotman BW. Gastrointestinal angiodysplasia. J Assoc Acad Minor Phys 1997; 8: 16-9.
7. Marwick T, Kerlin P. Angiodysplasia of the upper gastrointestinal tract. Clinical spectrum in 41 cases. J Clin Gastroenterol 1986; 8: 404-7.
8. Junquera F, Saperas E, de Torres I, Vidal MT, Malagelada JR. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999; 94: 1070-6.
9. Heidt J, Langers AM, van der Meer FJ, Brouwer RE. Thalidomide as treatment for digestive tract angiodysplasias. Neth J Med 2006; 64: 425-8.
10. Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003; 98: 221-2.
11. Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 2004; 53: 609-12.
12. Kirkham SE, Lindley KJ, Elawad MA, Blanshard C, Shah N. Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide. J Pediatr Gastroenterol Nutr 2006; 42: 585-7.
13. Dabak V, Kuriakose P, Kamboj G, Shurafa M. A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. Dig Dis Sci 2008; 53: 1632-5.
14. Kamalaporn P, Saravanan R, Cirocco M etal. Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. Eur J Gastroenterol Hepatol 2009; 21: 1347-50.
15. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996; 271: 17771-8.
16. Guillemin K, Krasnow MA. The hypoxic response: huffing and HIFing. Cell 1997; 89: 9-12.
17. Huang YF, Yang CH, Huang CC, Tai MH, Hsu KS. Pharmacological and genetic accumulation of hypoxia-inducible factor-1alpha enhances excitatory synaptic transmission in hippocampal neurons through the production of vascular endothelial growth factor. J Neurosci 2010; 30: 6080-93.
18. Yamakawa M, Liu LX, Date T etal. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 2003; 93: 664-73.
19. Singh H, Milner CS, Aguilar Hernandez MM, Patel N, Brindle NP. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases. Cell Signal 2009; 21: 1346-50.
20. Kume T. Novel insights into the differential functions of Notch ligands in vascular formation. J Angiogenes Res 2009; 16 (1): 8.
21. Viazis N, Papaxoinis K, Theodoropoulos I etal. Impact of capsule endoscopy in obscure small-bowel bleeding: defining strict diagnostic criteria for a favorable outcome. Gastrointest Endosc 2005; 62: 717-22.
22. Das A, Fanslow W, Cerretti D, Warren E, Talarico N, McGuire P. Angiopoietin/Tek interactions regulate MMP-9 expression and retinal neovascularization. Lab Invest 2003; 83: 1637-45.
23. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002; 99: 11205-10.
24. Holash J, Maisonpierre PC, Compton D etal. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8.
25. Hellström M, Phng LK, Hofmann JJ etal. Dll4 Signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007; 445: 776-80.
26. Kim YH, Hu H, Guevara-Gallardo S, Lam MT, Fong SY, Wang RA. Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis. Development 2008; 135: 3755-64.
27. Krebs LT, Xue Y, Norton CR etal. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev 2000; 14: 1343-52.
28. Limbourg FP, Takeshita K, Radtke F, Bronson RT, Chin MT, Liao JK. Essential role of endothelial Notch1 in angiogenesis. Circulation 2005; 111: 1826-32.
29. Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev 2004; 18: 2469-73.
30. Krebs LT, Starling C, Chervonsky AV, Gridley T. Notch1 activation in mice causes arteriovenous malformations phenocopied by ephrinB2 and EphB4 mutants. Genesis 2010; 48: 146-50.
31. ZhuGe Q, Zhong M, Zheng W etal. Notch-1 signalling is activated in brain arteriovenous malformations in humans. Brain 2009; 132: 3231-41.
32. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-5.
33. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363: 1802-11.
34. Sharma NL, Sharma VC, Mahajan VK, Shanker V, Ranjan N, Gupta M. Thalidomide: an experience in therapeutic outcome and adverse reactions. J Dermatolog Treat 2007; 18: 335-40.
35. Tabata C, Tabata R, Kadokawa Y etal. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007; 179: 708-14.